Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIb study of cannabidiol for the prevention of acute Graft versus Host Disease GvHD following allogeneic hematopoietic cell transplantation (HCT).

Next Previous
X
Search
Trial Profile

Phase IIb study of cannabidiol for the prevention of acute Graft versus Host Disease GvHD following allogeneic hematopoietic cell transplantation (HCT).

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use

    • Most Recent Events

    • 20 Sep 2018 According to a Kalytera Therapeutics media release, the company plans to announce interim data from the study later this year and expects to complete the study in Q2 2019.
    • 20 Sep 2018 According to a Kalytera Therapeutics media release, the company is expanding this study to include one additional site in Israel, and up to four additional sites in other jurisdictions, including Australia.
    • 07 Dec 2017 According to a Kalyteta Therapeutics media release, the principal investigator of the study is Daniel Couriel, M.D., M.S., Director of the Bone Marrow Transplant Program at the University of Utah Health Sciences, School of Medicine.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top